Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelagliptin 25 mg once-weekly in type 2 diabetes with severe renal impairment or end-stage renal disease
jRCT2080222918Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trelagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Started Jul 2015; status: completed.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080222918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222918.